Document is current
Any future updates will be listed below
-
Authors
Nguyen, Doan C. http://orcid.org/0000-0002-5389-6731
Hentenaar, Ian T.
Morrison-Porter, Andrea
Solano, David
Haddad, Natalie S. http://orcid.org/0000-0002-1348-3094
Castrillon, Carlos
Runnstrom, Martin C.
Lamothe, Pedro A. http://orcid.org/0000-0001-9262-2920
Andrews, Joel
Roberts, Danielle
Lonial, Sagar
Sanz, Ignacio http://orcid.org/0000-0003-4182-587X
Lee, F. Eun-Hyung http://orcid.org/0000-0002-6133-5942
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI172254, R01AI121252, 1P01AI125180, U01AI141993, 1P01AI125180, U54CA260563, 1P01AI125180)
Bill and Melinda Gates Foundation (INV-002351)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32HL116271, T32HL116271)
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 29 August 2024
First Online: 27 September 2024
Competing interests
: F.E.-H.L. is the founder of Micro-Bplex, Inc., serves on the scientific board of Be Biopharma, is a recipient of grants from the BMGF and Genentech, Inc., and has served as a consultant for Astra Zeneca. I.S. has consulted for GSK, Pfizer, Kayverna, Johnson & Johnson, Celgene, Bristol Myer Squibb and Visterra. F.E.-H.L., D.C.N. and I.S. are inventors of the patents concerning the plasma cell survival media related to this work (US11124766B2, US11125757B2 and Notice of Allowance issued 8/5/2024 for USPTO Patent Application 17/405,918). The other authors declare no competing interests.
